Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Cancer Therapies02:49

Cancer Therapies

10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

54
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
54
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utility of Flow Cytometry for Prognostic Prediction in Adult T-Cell Leukemia/Lymphoma.

EJHaem·2026
Same author

Transferrin Receptor Marks a Foxp3-Low Treg-like Inflammatory T Cell Subset Associated with Disease Severity in HAM/TSP.

Pathogens (Basel, Switzerland)·2026
Same author

Impact of sentinel lymph node biopsy versus axillary lymph node dissection on shoulder range of motion in early rehabilitation after breast cancer surgery.

Breast cancer (Tokyo, Japan)·2026
Same author

HTLV-1 Tax Reshapes the DNA-Binding Pattern of Transcription Factor IRF4 and Disrupts Host Gene Regulation.

Cancer science·2026
Same author

Polycomb repressive complexes as therapeutic targets in hematologic malignancies.

Experimental hematology·2025
Same author

Correction: A comprehensive assessment using multiple factors based on HAS-Flow analysis predicts ATL development and progression.

Scientific reports·2025

Related Experiment Video

Updated: Feb 27, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

8.8K

Targeting EZH2 in cancer therapy.

Makoto Yamagishi1, Kaoru Uchimaru

  • 1Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Current Opinion in Oncology
|July 1, 2017
PubMed
Summary

Enhancer of zeste homolog 2 (EZH2) is a key regulator of chromatin and epigenetics in cancer. Targeting EZH2 with small molecules shows promise for developing precise new cancer therapies.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K
Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells
12:13

Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells

Published on: August 23, 2014

11.3K

Related Experiment Videos

Last Updated: Feb 27, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

8.8K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K
Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells
12:13

Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells

Published on: August 23, 2014

11.3K

Area of Science:

  • Epigenetics and Molecular Biology
  • Cancer Therapeutics
  • Chromatin Regulation

Background:

  • Enhancer of zeste homolog 2 (EZH2) is a master regulator of chromatin structure and gene expression.
  • Dysregulation of EZH2 is implicated in the development and progression of various cancers.
  • EZH2 influences tumorigenesis through mechanisms including tumor suppressor gene silencing and immune evasion.

Purpose of the Study:

  • To review recent advancements in understanding EZH2's role in cancer.
  • To explore the molecular basis for targeting EZH2 in cancer therapy.
  • To discuss the development of small molecules targeting EZH2 enzymatic activity.

Main Methods:

  • Review of current literature on EZH2 function and dysregulation in cancer.
  • Analysis of molecular mechanisms by which EZH2 promotes tumorigenesis.
  • Examination of preclinical and clinical development of EZH2 inhibitors.

Main Results:

  • EZH2 dysregulation is common across many cancer types, promoting tumor growth by silencing tumor suppressor genes.
  • EZH2 activity is linked to key cancer processes like NF-κB activation, microRNA silencing, and immune evasion.
  • Loss-of-function mutations in other epigenetic factors can create an "EZH2/PRC2-addicted" state in cancer cells.
  • Small molecule inhibitors targeting EZH2 enzymatic activity have advanced to early-phase clinical trials.

Conclusions:

  • The EZH2-mediated epigenome and transcriptome are critical in defining cellular identity.
  • Targeting EZH2 and its associated Polycomb Repressive Complex 2 (PRC2) offers a promising strategy for developing more precise and effective cancer medicines.